BioNxt Solutions Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hugh A. D. Rogers
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1820 Fir Street Vancouver BC Canada V6J 3B1
- IPO Date
- Nov 26, 2019
- Website
- xphyto.com
- Similar Companies
- Business
- BioNxt Solutions Inc. is a bioscience company specializing in next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. Its core products and services include proprietary platforms such as sublingual thin films (oral dissolvable films), precision transdermal skin patches, enteric-coated oral tablets, and a newly developed targeted chemotherapy drug delivery platform designed for cancer treatment and immunosuppressive therapies. These technologies focus on critical therapeutic areas including autoimmune diseases, neurological disorders, and longevity, aiming to improve patient adherence, bioavailability, and dosing accuracy. The company operates research and development facilities across North America and Europe, with a particular operational focus in Germany, targeting primarily European markets. Founded in 2019 and headquartered in Vancouver, British Columbia, BioNxt Solutions positions itself as a pioneer in delivering innovative patient-centric therapies by streamlining regulatory approval and commercialization pathways. Recent major developments include securing final patent grants from the Eurasian Patent Organization and the European Patent Office for its oral sublingual cladribine platform aimed at the treatment of multiple sclerosis, as well as signing a letter agreement to acquire full intellectual property rights and co-develop a sublingual chemotherapy drug formulation with a European partner. This collaboration encompasses prototype development, intellectual property filings, preclinical and clinical trials, and regulatory submissions, with BioNxt holding 100% IP rights and the partner receiving a capped royalty. The company has also completed important milestones such as a "fast-track" U.S. patent filing for its sublingual cladribine formulation and expanded its patent portfolio to cover key drug delivery innovations. In 2025, BioNxt focuses on advancing clinical trials, pursuing strategic partnerships with pharmaceutical and biotech companies to accelerate development and commercialization, expanding its sublingual therapy pipeline, and enhancing its manufacturing capabilities with state-of-the-art equipment in Europe. These initiatives underscore BioNxt’s strategic shift toward patient-friendly therapies for chronic and neurodegenerative conditions and its expansion into immunosuppressant and oncology markets. BioNxt Solutions trades on the Canadian Securities Exchange under the symbol BNXT, on OTC Markets as BNXTF, and on German exchanges, reflecting its international operational scope. Through robust intellectual property protection, a technology-first approach, and a growing product pipeline, BioNxt aims to transform drug delivery platforms to address significant unmet medical needs worldwide.
BioNxt Solutions Announces Closing of Shares for Debt Settlement
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Bionxt Solutions Provides Bi-Weekly MCTO Status Report
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces Change of Directors
XPhyto Therapeutics says director and founder Professor Dr Raimar Loebenberg receives leadership award from Canadian Society for Pharmaceutical Science
XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head
XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics realizing 'significant synergies' after integration of 3a-diagnostics GmbH
XPhyto Therapeutics announces appointment of Drahoslav Zdarek as the company's head of sales, Europe
Xphyto Therapeutics makes key appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
Xphyto Therapeutics makes appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight
XPhyto epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
XPhyto Therapeutics completes strategic acquisition of 3a-diagnostics GmbH
XPhyto Therapeutics closes its private placements for gross proceeds of C$7M